Letters

Treatment for haemophilia by postcode

BMJ 1997; 314 doi: https://doi.org/10.1136/bmj.314.7082.749 (Published 08 March 1997) Cite this as: BMJ 1997;314:749
  1. Christopher A Ludlam, Chairmana,
  2. Charles R M Hay, Vice chairmanb,
  3. Gerard Dolan, Treasurerc
  1. a United Kingdom Haemophilia Centre Directors Organisation, Haemophilia and Thrombosis Centre, Royal Infirmary, Edinburgh EH3 9YW
  2. b Haemophilia Centre, Royal Infirmary, Manchester
  3. c Haemophilia Centre, Queens Medical Centre, Nottingham

    Editor—Recently the United Kingdom Haemophilia Centre Directors Organisation issued evidence based guidelines on therapeutic products for treating haemophilia. Before finalisation the draft guidelines were circulated to professional societies, royal colleges, and departments of health and modified accordingly. The final guidelines were unanimously approved at the organisation's annual geneal meeting and published.1

    One recommendation was that the treatment of choice for haemophilia A was recombinant factor VIII concentrate (rFVIII). This is because plasma derived factor VIII concentrates (pdFVIII) still transmit viral infections—for example, those caused by non-lipid coated viruses such as hepatitis A and parvovirus—despite the incorporation of viral inactivation steps in the manufacturing process.2 3 At present the licenced rFVIIIs contain human …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe